Skip to main content

Curevac N.V.(CVAC-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume

Latest News

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
ACCESSWIRE - Thu Aug 18, 2:40AM CDT
ACCESSWIRE
Thu Aug 18, 2:40AM CDT
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced...
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
ACCESSWIRE - Thu Aug 18, 2:15AM CDT
ACCESSWIRE
Thu Aug 18, 2:15AM CDT
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the...
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
AccessWire - Tue Jul 5, 6:15AM CDT
AccessWire
Tue Jul 5, 6:15AM CDT
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA") today announced that it...
CureVac Announces Voting Results of General Meeting
AccessWire - Wed Jun 22, 3:35PM CDT
AccessWire
Wed Jun 22, 3:35PM CDT
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
AccessWire - Wed Jun 8, 3:40PM CDT
AccessWire
Wed Jun 8, 3:40PM CDT
TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today...
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
AccessWire - Wed Jun 8, 3:25PM CDT
AccessWire
Wed Jun 8, 3:25PM CDT
TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA") today announced that...
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
AccessWire - Wed May 25, 6:55AM CDT
AccessWire
Wed May 25, 6:55AM CDT
TÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and myNEO N.V., a...
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
AccessWire - Wed May 25, 6:45AM CDT
AccessWire
Wed May 25, 6:45AM CDT
TÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial...
CureVac (CVAC) Q1 2022 Earnings Call Transcript
Motley Fool - Fri Apr 29, 3:00AM CDT
Motley Fool
Fri Apr 29, 3:00AM CDT
CVAC earnings call for the period ending March 31, 2022.
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
AccessWire - Thu Apr 28, 6:50AM CDT
AccessWire
Thu Apr 28, 6:50AM CDT
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.